转移性骨肿瘤患者抗肿瘤药物不良事件分析

目的 探讨沈阳地区转移性骨肿瘤住院患者抗肿瘤药物不良事件发生的特点和规律,为转移性骨肿瘤患者合理应用抗肿瘤药物、减少不良事件的发生提供参考依据。方法 收集2004-2014年沈阳地区4家医院的转移性骨肿瘤患者的病历资料,分析患者不良事件发生的一般情况、所涉及的抗肿瘤药物及药物剂型、所涉及的器官或系统分布。结果 发生抗肿瘤药物不良事件的例数为8242例,累计不良事件30122例次,其中男性占61.64%,女性占38.36%;45~64岁的患者构成比为47.00%,≥45岁患者构成比为74.99%;不良事件构成比最高的药物类别为其他抗肿瘤药物及辅助治疗药,占39.91%;注射剂的比例最大,占95.43%;不良事件最多涉及到的器官或系统是消化系统,占22.63%。结论 转移性骨肿瘤患者使用抗肿瘤药物导致不良事件的药物流行病学调查可为临床合理用药、提高患者生存质量提供参考依据。

Drug adverse events in patients with metastatic bone tumors

Objective To explore clinical features of drug adverse events(DAEs) in patients with metastatic bone tumor treated with antitumor drug and to provide scientific basis for rational use of antitumor drug and reduction of DAEs.Methods Medical records 11238 metastatic bone tumor inpatients were retrospectively collected from 4 hospitals in Shenyang city between January 2004 through January 2014.Incidents of DAEs among the patients registered were analyzed by demographic characteristics, type and pharmaceutical dosage form, and organ and system distribution of the antitumor drugs used by the patients.Results A total of 30122 DAEs were identified among 8242 metastatic bone tumor inpatients during the period; of the inpatients with DAEs, 61.64% were male and 38.36% were female; 47.00% were at the ages of 45 to 64 years and 74.99% were aged over 45 years.Of the DAEs identified, 39.91% were induced by other antitumor drugs and supplementary therapy drugs and 95.43% were related to the injections of the antitumor drugs; digestive system was the mostly involved by the DAEs, accounting for 22.63% of all DAEs identified.Conclusion Researches on pharmacoepidemiological features of DAEs among inpatients with metastatic bone tumor under chemotherapy could promote rational drug antitumor drug use and reduce the incidence of DAEs.